Overview of Dr. Drilon
I am a medical oncologist who specializes in early drug development and thoracic oncology.
Office
530 East 74th Street
New York, NY 10021
Education & Training
University of the Philippines College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2013 - 2026
NJ State Medical License 2019 - 2025- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions.Audrey-Anne Lamoureux, Michael J Fisher, Lauriane Lemelle, Elke Pfaff, Pouneh Amir-Yazdani
Clinical Cancer Research. 2024-12-03 - 3 citationsNVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia
Cancer Discovery. 2024-12-02 - Precision Oncology: 2024 in Review.Matteo Repetto, Nicole Fernandez, Alexander Drilon, Debyani Chakravarty
Cancer Discovery. 2024-12-02
Press Mentions
FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers with NRG1 FusionsDecember 5th, 2024- In the US, Young and Middle-Aged Women Are Being Diagnosed with Lung Cancer at Higher Rates Than MenNovember 25th, 2024
- NVL-655: Promising New Option in Pretreated, Drug-Resistant ALK-Mutated NSCLCSeptember 30th, 2024
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
